XXXX outlook Earlier XXXX. we're Thank for last our happy We've we us we've over financial months. joining progress provided this made today, you and and results XXXX. the outlook X fourth XXXX are evening. year consistent our quarter released the our our and for Both our expectations, full also earnings for with with the
in of in XX% range but by Adjusted Performance To review, oncology elevation XXXX. the growth guidance of we ended of versus end our November, provided our with XXXX with of expenses impacted Suite. billion was low $XXX.X revenue continued EBITDA in million within $X.XX
I'll our pillars two, you our value on progress I growing of: and to value. allocating stakeholder operational Tonight, of capital expanding three, the Then shareholder creation business increase comment within our update one, on X organically; XXXX profitability; outlook, we for in open then and will our our which the XXXX after for Suite go questions numbers through our including visibility earnings, that. it evolving up will into products. and believe enhance initiatives, Performance John will we'll
pillar through established growth, of XX% first and approximately to Beginning onetime we XX% have revenue strong visibility with a the XXXX outlook recognition for Including in the adjusting business go achieving will guides conversions high organic contract after the which growth rate today, based to on of contracted we today detail. this announcements in and our of John range impacts, both pipeline. strength
announcing Now to let's details today. turn and of revenue we're significant the the agreements expansions
to This quarter, we announcements have revenue new share. X
million New geographies states. which renewed Advantage. a expanded legacy services importantly, with approximately serving The including X across and include to technology and of England, plan lines new first members, and members This contract multiple Evolent relationship with in business, NIA is large agreements plan, its Medicare customer, a health our a is
product increased our we also the of part of services As expansion, offerings. and scope
we'll million XXXX, at additional MSK services X.X cardiology, cover For and imaging tech typical an and across product members PMPMs.
the region year highlight want I competitive Second, will to offices group MSSP came so ACO, another XXXX. provider of large mid-Atlantic ACO to across from Care, our This their strength The the care for area. practice continues joined the Care area. that win our in Complex in work demonstrate catchment for patients, XX performance XX,XXX practice be and the primary Complex this MSSP in over our services using a
the anticipate of services, quarter to for the MSK deals in newer outlook other in will well model client in pipeline the with had closing with expansion long-standing with offering large and tech positioned as specialty the a Suite. number quarter well are the existing they year, In the strong for expansion there as and sales be Performance of a sales Suite half terms be and clients Performance strong The results further of from adjusted management what of significant due a of our for continues and demanding. first and a suggest a market's highlights, number final the growth seasonal we our to year. strong geographic Early both surgical Midwest organizations performance payer strong,
Finally, and top results than for renewal challenging XX% a our of a in proud represent revenue. more a which renegotiations, customers of environment XXXX. for we're Despite our and XXX% satisfaction logo client number had Suite Performance together XXXX, rate renewal of we our
contract year. in allow important several with extension believe to benefit and XXXX The contract includes confidence bring P&L relationship physician-friendly additional and this that our and also we patient represents that our Centene for Importantly, to value beyond. Centene will recently us the partnership. extension We our automation bear adjustments in extended an sees to initiatives
second margin Service you I to update expansion. Suite, pillar our and want Turning the of Performance Technology and both on businesses. to the
disclosed cover today, As issued set to Suite to experienced presentation we noted on fully X over Slide Services X the X through contract we the and in Suite. quickly costs medical moving rates in time improvement $XXX escalation in and in secured Performance the unusual January, In for for Technology we contracts improved X of of the cancer contracts earnings a are renegotiate X million XXXX. being goal November to
X exit also our $XXX now EBITDA than improvement the third QX higher Today, total rate, in investor previewed secured a in run that signed agreement. adjusted we million all January. we at conference we're agreements, reporting we projected an to compared have Across
basis increases approximately profitability additional Evolent's along to We oncology expansion contractual business. time suite book our sets go-forward available points for margin performance enhanced on current rate of the protections portfolio with of margin XXXX restores and table additional maturation for with the XXX believe over
the increases of continue be prior our with midpoint to forecast disclosures, in oncology XXXX Consistent at XX% to cost range. the we
confident creates XXXX guidance. As John we that conservative will discuss feel point later, starting for a assumption this
our and invest to and business, and Regarding continue to increased Services experience. margins better automation Technology drive efficiencies in we patient
Auth our now integrated new Intelligence. the The of our the relative markets. by platform, platform rate and returns end $XX our to acquired year. have costs achieve our test the early efficiency assets is XXXX run Based are in on we direct first and in rebranded track currently our this We is XXXX million coming Machinify on an of work, annualized live other expecting exceeding in Auth into into improvement to
these continue up. we the value be annually term, net expect ramped efforts over to Longer fully will of $XX million once
position Importantly, plans than is faster our service the cost reflects to that more more reinforces we and physicians, This believe this effective innovation fundamentally strong efficiency. market. health and in patients
we costs onetime in investment for our of outlook EBITDA reflected on accretive and implementation While and XXXX to XXXX a $XX million, meaningfully is today. that be adjusted expect to drag do beyond, work AI-based automation net this approximately
team a highly our of Finally, on investing focused be term, we term product our allocation, to excellence. the our near primarily plans regarding leverage. objectives efficient as in is in Longer third M&A internal reducing pillar our growth and operational expect growth capital strategic unchanged, priorities component and executing The executive accelerating of development are well.
me year enters position to industry numbers today. picture care the strength. we I detail, go and it in let believe XXXX the in through back step hand bigger highlight the After of Evolent in Before John we it a in tumultuous health XXXX, to as see
and growing We to problem-facing Americans. an solution important have a
our Suite narrowed We ranges have and clear contractually earnings for we're our business, forecast with ability Performance improved creation a shareholder pursuing to plan. value
example, disease population. increased due The first mark to extended to in X been for the as never in to new oncology, for cancer condition States advances Incredible therapies well as greater. significantly conditions cancers management record is a and targeted an the many cardiovascular cancer is growth this over time. high, X cancer like growing and have need diagnoses in surpassing lifespan give million complex cases aging cases for see To The United in many common million expected year, the for patients. contributed the
At the can same these cost the staggering. time, therapies be of
$XXX,XXX. checkpoint example, cost year's infusion inhibitor For nearly worth a can of Medicare
For certain clear the a therapy indications, benefit. provides
is instead deserve core precious and information science in resulting available pursuing to and best We clear, the providing access physicians is the our work. that to to others, For that are patients today, treatments less is that information that patients unlikely mission. believe clinical wasting time
We both Evolent peer-to-peer physician close peer-to-peer conducted to Evolent treating physicians technology patient XXXX, physicians. model conversations and and supports a with seeking points nuanced touch these physicians that conditions, That's clinically do our to XXX,XXX provides patients understand to In provide guidance to physician-to-physician interactions. and needs through their guidance to over day. believe X,XXX driven treating offer evidence-based each
XXX clinical recommendations are team the evidence able of an physicians volumes to Our individualized latest, real-time significant providing over relevant basis. and most of on analyze clinical review
clinically Our scientific and rapid in well advancement. believe, us positions a world we technological of focused approach,
key This often by increases outstanding results over work demonstrated We've that model also to evidence best adherence in today. conditions. has XX% our
the average, the collaboration time, of the year. in change evidence Evolent's payers. improvement we range, and and our satisfaction For and see At market for the ability credibility. engaged clinical example, patients after cancer above in Evolent and to physicians approximately before patient the has historically care, This same to the cost been best on market enters care often XX% at for staff scores drive adherence XX% to average least of XX% and a quality have from reduces Evolent demonstrating our that increases through in
crisis for and Americans, health the guided affordability aim would of mission In the to high able same ensure numbers. all that our era hitting balance also to family our At values Evolent. these values this is debt to own care pursue be our we by annual receiving that we We of national increases believe complex are we our want and treatments. have at an premium on core patients care
affordability of care believe many a of will interest physicians growing Evolent XX%. immediate to best patients' Association work, patients durable, tension, health need recent that and to part example, this first, study Blue showed inflation through important care Blue health health Cross physicians it care delicate years we what for of for to the cause a and and to system collaboration cost would removing similar For be but by Because the do the manage with does, with up come. Evolent Shield
to financial will the review our let me turn With outlook. and over that, highlights it XXXX who John,
